Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

April 30, 2013

Conditions
Hepatitis B, Chronic
Interventions
GENETIC

HB-110

Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.

Trial Locations (1)

137-701

Seoul St. Mary's Hospital, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT01641536 - Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients | Biotech Hunter | Biotech Hunter